￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Medical News

New treatment combination for EGFR mutated non-small cell lung cancer: Oleclumab + osimertinib

2025-10-19 11:44:20

Check Details
Lorlatinib is expected to enter the first-line drug field for lung cancer

2025-10-19 11:44:20

Check Details
Effect of Lorlatinib in first-line treatment of ALK-positive non-small cell lung cancer (NSCLC)

2025-10-19 11:44:20

Check Details
Lorlatinib approved by FDA for first-line treatment of ALK lung cancer

2025-10-19 11:44:20

Check Details
What benefits does cabozantinib (XL184) bring to patients? You will know after reading it_Kang Hule

2025-10-19 11:44:20

Check Details
Lorbrena can significantly prolong patient survival

2025-10-19 11:44:20

Check Details
[Patient Concern] Safety and Tolerability of Cabozantinib_ Kanghule

2025-10-19 11:44:20

Check Details
[Discover with you] Advantages of Lorlatinib

2025-10-19 11:44:20

Check Details
How much does the targeted drug larotrectinib (Vitrakvi) cost

2025-10-19 11:44:20

Check Details
Can larotrectinib be reimbursed by medical insurance

2025-10-19 11:44:20

Check Details
Is alectinib hydrochloride effective? Where to buy it

2025-10-19 11:44:20

Check Details
What is the effect of alectinib on the treatment of advanced lung cancer

2025-10-19 11:44:20

Check Details
Category
相关知识